Losartan Potassium
Product Images NDC 53002-2643

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-2643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (92296151 E507 41b4 A040 C01b87ecb982 01)

Chemical structure of Losartan Potassium, showing the molecular arrangement including the chlorinated pyrimidine ring, biphenyl moiety, and potassium ion (K+).*

FDA Label Image

Figure 2 (92296151 E507 41b4 A040 C01b87ecb982 02)

A line graph comparing the percentage of patients reaching the primary endpoint over 66 study months for Atenolol and Losartan Potassium Tablets. Atenolol is represented by a dotted line and Losartan Potassium Tablets by a solid line. The graph shows a 13% adjusted risk reduction for Losartan Potassium with a p-value of 0.021.*

FDA Label Image

Figure 3 (92296151 E507 41b4 A040 C01b87ecb982 03)

A line chart comparing the percentage of patients with fatal or non-fatal stroke over time in months for Losartan Potassium Tablets versus Atenolol. The chart includes an adjusted risk reduction of 25% with a p-value of 0.001, showing Losartan Potassium associated with a lower stroke rate over the study period.*

FDA Label Image

Figure 4 (92296151 E507 41b4 A040 C01b87ecb982 04)

A forest plot comparing the hazard ratios of Losartan Potassium tablets versus Atenolol for primary composite events and stroke (fatal/non-fatal) outcomes. The chart presents subgroup analyses by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease, displaying event rates, hazard ratios, and confidence intervals for each group.*

FDA Label Image

Figure 5 (92296151 E507 41b4 A040 C01b87ecb982 05)

A line graph comparing the percentage of patients with an event over time in months for Losartan Potassium Tablets versus Placebo. The solid line represents Losartan Potassium Tablets and the dotted line represents Placebo. The graph also includes a reported risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 06)

FDA Label Image

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 07)

FDA Label Image

Label Image (Lbl530022643)

Losartan Potassium 50 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label indicates a quantity of 100 tablets with instructions to take one tablet daily as directed. It includes prescription information, barcodes, lot number, expiration date, and placeholder text for clinic name and patient details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.